Cerulenin Blockade of Fatty Acid Synthase Reverses Hepatic Steatosis in ob/ob Mice

Gang Cheng1*, Arun P. Palanisamy1, Zachary P. Evans1, Alton G. Sutter1, Lan Jin1, Inderjit Singh2, Harold May3, Michael G. Schmidt3, Kenneth D. Chavin1

1 Divisions of Transplant Surgery, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, United States of America, 2 Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, United States of America, 3 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America

Abstract

Fatty liver or hepatic steatosis is a common health problem associated with abnormal liver function and increased susceptibility to ischemia/reperfusion injury. The objective of this study was to investigate the effect of the fatty acid synthase inhibitor cerulenin on hepatic function in steatotic ob/ob mice. Different dosages of cerulenin were administered intraperitoneally to ob/ob mice for 2 to 7 days. Body weight, serum AST/ALT, hepatic energy state, and gene expression patterns in ob/ob mice were examined. We found that cerulenin treatment markedly improved hepatic function in ob/ob mice. Serum AST/ALT levels were significantly decreased and hepatic ATP levels increased in treated obese mice compared to obese controls, accompanied by fat depletion in the hepatocyte. Expression of peroxisome proliferator-activated receptors α and γ and uncoupling protein 2 were suppressed with cerulenin treatment and paralleled changes in AST/ALT levels. Hepatic glutathione content were increased in some cases and apoptotic activity in the steatotic livers was minimally changed with cerulenin treatment. In conclusion, these results demonstrate that fatty acid synthase blockade constitutes a novel therapeutic strategy for altering hepatic steatosis at non-stressed states in obese livers.

Introduction

Hepatic steatosis or fatty liver is an increasingly common health problem due to accumulation of fat within hepatocytes. In Western countries, up to one third of the general population is affected by hepatic steatosis [1,2,3], and is now the most common cause of chronic liver disease in children and adolescents [4]. Hepatic steatosis has been associated with increased sensitivity of the liver to other injuries, such as insulin resistance [2] and ischemia/reperfusion (I/R) during transplantation [5]. A substantial number of patients with hepatic steatosis may finally develop cirrhosis [5,6]. This raises an even greater public health concern as it is recognized that cirrhosis has a 10-year liver-related mortality of 25% [1,3].

Lipid accumulation inside of hepatocytes is associated with a number of intracellular disorders including mitochondrial abnormalities [7], impaired ability to synthesize ATP [8,9], and increased generation of reactive oxygen species (ROS) [10,11]. Uncoupling protein 2 (UCP2), which uncouples mitochondrial oxidative phosphorylation and thus depletes intracellular ATP, has been associated with hepatic steatosis [9]. We have previously demonstrated that UCP2 expression in the livers of obese ob/ob mice is markedly increased, which may contribute to a high mortality and slower recovery from I/R injury [12]. Accumulating evidence suggests that fatty acids induce UCP2 expression in hepatocytes [12,13,14], and this activation could be mediated by peroxisome proliferator-activated receptors (PPARs) [13,15]. In addition, increased production of ROS has been observed in steatotic livers [7,16], which may be responsible for the progression from steatosis to cirrhosis [17,18].

Excess fat plays a central role in the pathogenesis of hepatic steatosis, and that the effects of excess fat are mediated by PPARs and UCP2 overexpression [13]. The natural product cerulenin ([2R,3S]-2,3-epoxy-4-oxo-7,10-trans,trans-dodecadienamide) is a mycotoxin originally developed as an antifungal antibiotic but has potent inhibitory effect on fatty acid synthase (FAS) [19,20]. Cerulenin binds covalently to a cysteine residue at the active site of the condensing enzyme and irreversibly inhibits β-ketoacyl-ACP synthase activity of FAS [21,22]. Previously, cerulenin has been shown to cause sustained weight loss and decreased fat pad size [23,24,25] and increase viability following I/R in ob/ob mice [26]. The objectives of this study were to investigate whether and how cerulenin improves steatotic liver function in ob/ob mice, in the basal non-stressed state.

Materials and Methods

Ethics Statement

The use of animals is necessary in this study because of the nature of information sought. All rodents used for surgeries were
initially anesthetized using isoflurane in desiccators then followed by isoflurane as needed. Animals were observed post-operatively for signs of distress as in respiratory distress, blood pressure, and discernable pain. Buprenorphine was given as an analgesic drug to reduce pain and discomfort. Animals are removed from the study and euthanized by exsanguination (under anesthesia) or CO2 when clearly suffering negates the need to continue humanely in accordance with the Medical University of South Carolina’s Institutional Animal Care and Use Committee (IACUC) policy. This study was reviewed and approved by the Medical University of South Carolina’s IACUC (AR# 3003: Effects of Steatosis on Ischemia/Reperfusion and Liver Regeneration).

Animals

*ob/ob* mice [Jackson Laboratory, ME] are obese with hepatic steatosis as a result of homozygous leptin gene deficiency. Mice were housed 3 to 4 per cage in a pathogen-free temperature-controlled room (22–24°C) with a 12-hour light-dark cycle and provided with water and food available *ad libitum*. All animals received humane care and all animal experiments have been reviewed and approved by the university Institutional Animal Care and Use Committee (IACUC).

Cerulenin Treatment

Cerulenin (Sigma) was given to 6–8 week old male *ob/ob* mice in RPMI medium containing 20% DMSO intraperitoneally (i.p.) as previously described [24,27]. Controls were injected similarly with vehicle alone. The experimental groups (4 mice each) were as follows: A: 60 mg/kg/day cerulenin, injected daily for 7 days; B: 60 mg/kg every other day for 7 days; C: 30 mg/kg/day for 7 days; D: 30 mg/kg every other day for 7 days; E: vehicle, daily for 7 days; F: 60 mg/kg/day cerulenin for 2 days; G: 30 mg/kg/day cerulenin for 2 days; H: vehicle, daily for 2 days; I: control. All animals were sacrificed on the same day under anesthesia. Blood was collected by portal vein puncture. Liver samples were snap-frozen in liquid N2 and stored at –80°C until analysis, or paraformaldehyde-fixed for histological analysis.

Serum Aminotransferases

Collected blood was allowed to clot at room temperature for 15 minutes, centrifuged at 3500 g for 5 minutes to collect serum, and evaluated for AST/ALT by a Coulter counter from the university Clinical Laboratory Services.

ATP Assay

Cellular ATP content was analyzed in triplicate as described previously [28]. For normalization between samples, total cellular protein from each sample of tissue homogenate was determined by BCA assay.

Northern Blot Analysis

Murine UCP2 cDNA was a gift from Dr. Paul Dowell (Johns Hopkins University). Mouse PPARz and γ cDNAs were made by RT-PCR according standard protocols, and the primer sequences are available upon request. Total cellular RNA preparations and Northern blot were performed as described previously [28]. For normalization, the blots were stripped and re-hybridized with 18 S RNA cDNA probe.

Immunohistochemistry

Rabbit anti-PPARγ antibody (Alexis Biochemicals, Germany, 1:1000 dilution) was used to detect PPARγ expression in the liver in paraformaldehyde-fixed, paraffin-embedded liver sections according to standard techniques [29].

Histochemical Analysis

H&E staining was performed in paraffin-embedded liver sections, while Oil-Red-O staining (ORO) staining was used on frozen sections to avoid fat solvents used in processing paraffin sections, according to standard protocols.

Gas Chromatography-flame Ionization Detection (GC-FID) Analysis of Lipid Content

Fatty acid (FA) from liver samples were extracted as described before [30]. Liver homogenates were separated by organic
separation filter. BF3-10% methanol was added to catalyze the methanolysis of the fats to FA methyl esters and an internal standard was added before each run. Samples (1 ml) were injected by an Agilent auto sampler into an RTX-624 capillary column of a Hewlett-Packard 5890 GC (Agilent).

Column temperature was held at 40°C for 2 min, followed by a temperature ramp of 20°C/min to 315°C where the column was held for a minimum of 5 minutes. A FA methyl esters standard mix was used to standardize the instrument and analyze the samples.

GSH Assay

Micro titer plate assay for the measurement of glutathione and glutathione disulfide was done as described previously [31]. All reagents were from Sigma.

In Situ Detection of Apoptosis

TUNEL assay was done in paraformaldehyde-fixed, paraffin-embedded liver sections according to standard techniques [32].

Statistical Analysis

Statistical significance was determined by chi-square test for viability assay, and by a two-tailed Student’s t test for all other analyses. Data are presented as the mean±SD and a p value of <0.05 was considered statistically significant.

Results

Cerulenin Decreases Weight Gain in ob/ob Mice

Cerulenin treatment of ob/ob mice had obvious effects on body weight. With 2 days of treatment, body weight in treated mice was decreased compared to a 5.7% weight gain in the controls. With prolonged (7 days) treatment, no body weight loss was observed, but body weight gain was slowed. In all groups, 60 mg/kg of cerulenin was more effective than 30 mg/kg in inhibiting weight gain (Fig. 1).

Cerulenin Improves Liver Function in ob/ob Mice

ob/ob mice usually have baseline hepatitis as evidenced by increased AST/ALT levels. In our experiments, we found that there was no difference in serum aminotransferase (AST/ALT) levels between baseline control and vehicle-treated mice (data not shown). However, 60 mg/kg cerulenin, given either daily or every other day for 7 days, significantly reduced both AST and ALT in treated mice compared with 7-day vehicle-treated controls, with serum AST/ALT levels decreased 69.1% and 71.8% respectively after daily treatment (Fig. 2A), and decreased 69.8% and 78.5% respectively after every other day treatment. It is interesting to note that cerulenin at 60 mg/kg/day given for 2 days was as effective as 7 days of treatment in improving liver function, with serum AST/ALT levels decreased by 53.8% and 66.1% respectively in treated mice compared with 2-day vehicle-treated controls (Fig. 2A). In contrast, 30 mg/kg cerulenin at all dosage regimes decreased AST and ALT but did not achieve any statistical significance (Fig. 2A).

Cerulenin Increases ATP Level in the Livers of ob/ob Mice

We have previously demonstrated that ATP levels in steatotic mice are lower than lean mice [9,33]. Given an improvement in hepatic function in the ob/ob mice with FAS blockade, we next sought to determine if this would also affect ATP content. We found that if given daily or every other day, ATP content were increased 58.1% and 61.5% respectively by 7-day treatment of 60 mg/kg cerulenin (Fig. 2B). Significant ATP elevation was also observed with only 2 days of treatment with 60 mg/kg cerulenin (Fig. 2B). In contrast, 30 mg/kg cerulenin, given either 2 or 7 days, did not show any significant effect on cellular ATP content.

Cerulenin Decreases Fat Content and Alters the Fat Type

The gross appearance of cerulenin treated steatotic livers improved. While fatty livers in the control group were yellowish, pale, and larger in size, cerulenin treated steatotic livers looked dark-brown and smaller, a phenotype more consistent with non-fatty (normal) livers. H&E staining of these specimens revealed that fat content in cerulenin-treated livers was much less than the controls (a phenomenon not observed in vehicle-treated controls), with the most obvious morphological improvement in the centrilobular zone (Fig. 3A–C). To analyze changes in fat content in these samples, ORO was performed on freshly frozen liver sections. The histological profile of ob/ob livers that received cerulenin treatment demonstrated a dramatic reduction in lipid content, which was dose and time dependent. Seven-day treatment of 60 mg/kg cerulenin daily or every other day demonstrated the greatest decrease of fat staining and in some...
areas of the liver, ORO staining was absent (Fig. 3D–F). Two-day treatment of 60 mg/kg cerulenin resulted in a modest reduction in fat content. In contrast, cerulenin given 30 mg/kg was less effective than 60 mg/kg doses, but its effect on fat content was still obvious except for 2-day treatment (data not shown).

Generally, the steatosis observed in the control animals was predominantly macrovesicular, and the hepatocyte nuclei were displaced into the periphery of the cell by a large fat droplet. Upon treatment with cerulenin, the size of the fat droplets decreased, suggesting a conversion from macrosteatosis to microsteatosis (Fig. 3D–F). The computer program NIH Image was employed for analysis of fat content in 7-day treated livers. The percentage of fat observed in the liver cross-sections decreased from an average of 9.77% ± 4.2% in the vehicle control to 2.92% ± 0.5% in the animals treated with 60 mg/kg/day of cerulenin (p < 0.05) and 5.75% ± 1.8% with 30 mg/kg/day cerulenin (Fig. 3G). Similarly, we analyzed the radii of fat droplets with NIH Image for all fat particles with a diameter of at least 2 μm, and found that the radii of fat droplets decreased from 3.57 ± 0.84 μm in the vehicle control to 1.79 ± 0.36 μm in the animals treated with 60 mg/kg/
day of cerulenin (p<0.05) and 2.48±0.20 μm with 30 mg/kg/day of cerulenin (Fig. 3H).

The differences in fat content with cerulenin treatment prompted us to explore changes in the primary FA composition in these samples by gas chromatography-flame ionization detection (GC-FID). All samples with 7-day daily cerulenin treatment were analyzed and data was presented as the area under the curve of each type of FA. This analysis revealed that all FAs were not affected to the same extent by cerulenin treatment. The content of some FAs, including capric acid, myristic acid, C17 diene acid, Cis-5,8,11,14,17-eicosapentaenoic acid and arachidonic acid, were maintained at approximately the same level, while the content of others (including palmitoleic acid, palmitic acid, stearic acid, oleic/C18 acid and elaidic acid) were significantly decreased with different dosages of cerulenin treatment (Fig. 4).

**Cerulenin Treatment Decreases UCP2 and PPAR Expression**

Steatotic livers have upregulated UCP2 [9,34,35] and PPARα and γ [36,37] which play a role in FA metabolism, we thus examined whether the beneficial effects of FAS inhibition on steatotic liver were mediated by the expression of UCP2 and PPARs. Consistent with the above ATP data, we found that UCP2 mRNA expression in ob/ob mouse livers was decreased by 7-day treatment of 60 mg/kg cerulenin, while a similar treatment using 30 mg/kg cerulenin had shown no detectable effect (Fig. 5A). The same pattern of changes in the expression of PPARα and γ were also observed. Both of these signaling molecules had decreased mRNA expression with 60 mg/kg of cerulenin treatment (7 days) but not with 30 mg/kg of cerulenin (Fig. 5A). Treatment with vehicle alone failed to change mRNA levels of UCP2, PPARα and PPARγ compared to unmanipulated animals (data not shown). Densitometric analysis of the mRNA levels visualized via Northern blot demonstrates that these changes were statistically significant (Fig. 5B). Immunohistochemical staining of PPARγ confirmed similar change at the protein level (Fig. 5C&D).

**Cerulenin has a Minimal Effect on Apoptotic Activity in the Liver**

It has been demonstrated that administration of cerulenin and other FAS inhibitors in cancer tissues is cytotoxic and induces apoptosis [38,39]. We carefully examined H&E staining of liver samples from each group, and failed to find any evidence of cytotoxicity associated with cerulenin administration. In order to clarify this question, TUNEL assay was performed in order to determine the distribution of apoptotic cells within the liver samples. We found apoptotic cells in some of the groups that received 60 mg/kg cerulenin but not in groups that received 30 mg/kg cerulenin (Fig. 6A). However, the number of apoptotic cells observed in samples from 60 mg/kg cerulenin treatment was very low, never exceeding a value greater than 0.1% of the total cell population. These data suggested that at the doses investigated cerulenin was not appreciably toxic to steatotic livers.

**Cerulenin Treatment does not Increase ROS Production**

UCP2 reduces production of ROS within cells as a result of decreased mitochondrial membrane potential [40]. Since steatotic livers have intrinsically higher levels of ROS [7], the downregulation of UCP2 in steatotic livers by cerulenin raises a concern that this might result in an increased production of ROS. We thus measured cellular glutathione (GSH) levels in the liver from each experimental group. GSH is the major intracellular antioxidant that acts as the immediate donor of electrons to neutralize H2O2 and as a scavenger of oxygen and nitrogen-based free radicals [41]. An increased production of ROS in steatotic livers will therefore result in reduced GSH content. Vehicle alone did not change GSH content in the steatotic liver (data not shown).
controls. only slightly increased GSH levels over the vehicle and baseline significant. Short-term treatment (2 days) of cerulenin resulted in dose were also increased but the elevation was not statistically values are expressed as averages standardized to baseline. 18 S RNA was used for normalization.

Discussion

In this study, we addressed the hypothesis that excess fat plays a central role in the pathogenesis of hepatic steatosis resulting from the overexpression of PPAR\(\alpha\), PPAR\(\gamma\), and UCP2. In order to address this hypothesis, cerulenin was used to determine if FAS blockade could effectively ameliorate the pathogenesis of hepatic steatosis. Blockade of FAS was found to effectively deplete fat content, increase intracellular ATP levels, and improved hepatic function. This study also suggests that these effects were mediated by suppressed expression of PPAR\(\alpha\), PPAR\(\gamma\), and UCP2. We have previously demonstrated that \(ob/ob\) livers have decreased ATP content and increased UCP2 expression [12]. Based on the facts that UCP2 expression is increased in steatotic livers and that steatotic livers have reduced ATP content and impaired liver function, we hypothesized that overexpression of UCP2 would be harmful to steatotic hepatocytes [12,20]. Indeed, in this study, new evidence was generated that the hepatic ATP levels are inversely related to UCP2 expression. These results, together with our previous findings, strongly suggest that overexpression of UCP2 in the steatotic liver is detrimental to normal liver function, and the protective effects of cerulenin to the fatty liver are at least partially through decreased UCP2 expression.

PPARs are nuclear receptors that bind to specific PPAR response elements in the promoter region of their target genes [42] and regulate genes involved in lipid utilization, storage and lipoprotein metabolism [43,44,45]. PPAR\(\gamma\) is highly expressed in adipose tissues [46] and plays a critical role in the differentiation of adipocytes [47,48] and in adipogenesis [49]. PPAR\(\alpha\) is a key controller of intermediary metabolism and transcriptionally regulates a number of genes involved in FA oxidation [43,50]. It is well documented that PPAR\(\alpha\) and \(\gamma\) expression are upregulated by FAs [51] and that the effects of FAs on UCP2 expression regulation are through PPAR mediated pathways [52]. FAs and other ligands specific to PPAR\(\alpha\) promote UCP2 expression in neonatal cardiomyocytes [15]. Adipose tissues treated with BRL49653 and bromopalmitate, two potent activators of PPAR\(\gamma\), have increased UCP2 mRNA levels [53]. Mice treated with pioglitazone, a specific stimulant of PPAR\(\gamma\), show increased UCP2 mRNA levels in the skeletal muscle [54]. Since UCP2 upregulation inhibits ATP synthesis, we hypothesized that depleted ATP levels and impaired hepatic function in steatotic livers are triggered by excess fat, which in turn activates PPAR\(\alpha\) and \(\gamma\), and upregulates UCP2. In the present study, we noticed the corresponding changes in the expressions of PPARs and UCP2, ATP and the fat content, in \(ob/ob\) livers treated with cerulenin, which support our hypothesis. In fact, treatment of obese and diabetic mice with the selective PPAR\(\gamma\) activator thiazolidinediones has been reported to result in centrilobular steatosis in the liver [55], and disruption of PPAR\(\gamma\) in \(ob/ob\) mice has been shown to be beneficial to the liver [56]. In our experiments, we found that with fat depletion, the expression of PPAR\(\alpha\), PPAR\(\gamma\), and UCP2 were decreased, accompanied by increased ATP content and improved hepatic function. In this cascade of signaling, we believe that PPAR\(\alpha\) and \(\gamma\) are downstream signaling molecules of excess fat but upstream regulators of UCP2 expression. This explains why fat depletion leads to elevated ATP levels and improved liver function.

Two factors may limit the usefulness of cerulenin in improving hepatic function: increased ROS production and apoptosis. The production of ROS is positively related to mitochondrial membrane potential and the level of coupling of mitochondrial respiration to ATP production. It has been reported that UCP2 expression decreases production of ROS due to its effect on mitochondrial membrane potential [57]. Also, cerulenin treatment may lead to apoptosis in cancer tissues [58,59]. However, controversy exists in regard to the role of UCP2 in the production of ROS. In the liver of \(ob/ob\) mice and in primary culture, hepatocytes produce increased amounts of ROS while the UCP2 level is high [11]. In our experiments, we did not observe any significant decrease in GSH level with cerulenin treatment. Instead, we found GSH contents significantly increased (indicating decreased production of ROS) in some cerulenin treated \(ob/ob\) mice when UCP2 expression was downregulated. We noted that mice with higher GSH contents had the most dramatic fat decrease. Given that excess lipid oxidation and/or excess lipid storage leads to increased ROS production [35], our results...
suggest that the effect of reduced UCP2 expression on ROS production is well offset by profound decreases in fat content, which help to lower ROS levels. Our data also demonstrate that cerulenin at 60 mg/kg had no obvious cytotoxic effect in the steatotic livers, and apoptotic activity was only marginally affected.

In summary, the FAS blocker cerulenin effectively depleted fat content in the steatotic liver, which triggered a series of reactions: expression of PPARα and γ were decreased resulting in lower UCP2 level and increased hepatic ATP content, and decreased ROS production. Increased intracellular ATP levels and decreased ROS ultimately improved liver function. Currently, there is no effective treatment for hepatic steatosis. We believe these findings have significant clinical importance as a potential new therapeutic strategy for hepatic steatosis in general and for steatotic livers subjected to I/R injury.

**Author Contributions**

Conceived and designed the experiments: GC AP ZE HM IS MS KC. Performed the experiments: GC AP ZE AS LJ. Analyzed the data: GC AP ZE. Contributed reagents/materials/analysis tools: IS HM MS KC. Wrote the paper: GC AP ZE.

**References**

1. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21: 17–26.

2. Angulo P (2005) Nonalcoholic fatty liver disease. Rev Gastroenterol Mex 70 Suppl 3: 52–56.

3. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99–S112.

4. Della Corte C, Alii A, Sacca A, De Vito R, Vania A, et al. (2012) Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health 51: 305–312.

5. Nadig SN, Periyasamy B, Shafizadeh SF, Polito C, Fiorini RN, et al. (2004) Hepatocellular ultrastructure after ischemia/reperfusion injury in human orthotopic liver transplantation. J Gastrointest Surg 8: 695–700.

6. Malnick SD, Beergabel M, Knebler H (2003) Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 96: 699–709.

7. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B (2013) Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology.

8. Basaranoglu M, Basaranoglu G, Senturk H (2013) From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 19: 1150–1165.

9. Evans ZP, Palanisamy AP, Sutter AG, Elliott JD, Ramshesh VK, et al. (2012) Mitochondrial uncoupling protein-2 deficiency protects steatotic mouse livers.
Fatty Acid Synthase Blockade on Steatosis

35. Cortez-Pinto H, Zhi Lin H, Qi Yang S, Odwin Da Costa S, Diehl AM (1999) Fatty acid synthase inhibition in cancer cells: why does it really matter? Gut 55:123–130.

36. Memon RA, Trento LH, Nonogaki K, Benignus V, Moser AH, et al. (2000) Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsiveness adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141:4021–4031.

37. Rahimian R, Masih-Khan E, Lo M, van Breeemen C, McManus BM, et al. (2001) Hepatic over-expression of peroxisome proliferator activated receptor gamma in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem 224:29–37.

38. Pizer ES, Jackisch C, Wood FD, Pastermark GR, Davidson NE, et al. (1996) Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745–2747.

39. Tomasi JN, Pinn ML, Kuhajda FP (2001) Fatty acid synthesis inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochim Biophys Res Commun 285:217–223.

40. Guan LL, Wang YF, Gong DZ, Yuan B, Wu Q, et al. (2012) [Establishment of the Chang liver cell line stably overexpressing human UCP2 gene and its effect on mitochondrial membrane potential and reactive oxygen species]. Zhonghua Gan Zang Bing Za Zhi 20:131–135.

41. Armenti T, Ghiassii R, Balercia G, Gelli L, Jasiem W, et al. (2000) Glutathione and ultrastructural changes in inflow occlusion of rat liver. J Surg Res 80:207–214.

42. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR-gamma 2, a lipid-activated transcription factor. Cell 79:1147–1156.

43. Francis GA, Fayerd E, Picard F, Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261–311.

44. Dongiovanni P, Valentini L (2013) Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility? PPAR Res 2013:452061.

45. Gres S, Canteiro J, Mercader J, Carpenne C (2013) Oxidation of high doses of sorbinil favors lipid accumulation in mouse and human fat cells. Mol Nutr Food Res.

46. de Las Heras N, Valero-Munoz M, Ballisteros S, Gomez-Hernandez A, Martin-Fernandez B, et al. (2013) Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet. Nutr Metab Cardiovasc Dis.

47. Suzuki S, Suzuki M, Sembon S, Fuchimoto D, Onishi A (2013) Characterization of mechanisms of oxatamate on porcine preadipocytes and adipocytes differentiated in vitro. Biochim Biophys Res Commun 432:92–98.

48. Spiegelman BM, Puigserver P, Wu Z (2000) Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 24 Suppl 4:S8–S10.

49. Tang QQ, Lane MD (2012) Adipogenesis from stem cell to adipocyte. Annu Rev Biochem 81:715–736.

50. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244–251.

51. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435.

52. Medvedev AV, Snedden SK, Raimbault S, Ricquier D, Collins S (2001) Peroxisome proliferator-activated receptor-gamma-dependent activation of pyruvate dehydrogenase kinase-4 in non-alcoholic insulin resistant human adipocytes. Proc Natl Acad Sci USA 98:1147–1151.

53. Vigneri-Bascands N, Sahlburn-Blache JS, Dandine M, Dauzats M, Daviaud D, et al. (1999) Increase in uncoupling protein-2 mRNA expression by BRL49653 in vivo. Biochim Biophys Acta 1447:120–125.

54. Shimokawa T, Kato M, Watanabe Y, Hirayama R, Kurosaki E, et al. (1998) In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in Zucker diabetic fatty rats. Biochem Pharmacol 56:115–119.

55. Tontonoz P, Hu E, Spiegelman BM (1999) Stimulation of adipogenesis in fibroblasts by PPAR-gamma 2, a lipid-activated transcription factor. Cell 79:1147–1156.

56. Francis GA, Fayerd E, Picard F, Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261–311.

57. Dongiovanni P, Valentini L (2013) Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility? PPAR Res 2013:452061.

58. Gres S, Canteiro J, Mercader J, Carpenne C (2013) Oxidation of high doses of sorbinil favors lipid accumulation in mouse and human fat cells. Mol Nutr Food Res.

59. de Las Heras N, Valero-Munoz M, Ballisteros S, Gomez-Hernandez A, Martin-Fernandez B, et al. (2013) Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet. Nutr Metab Cardiovasc Dis.

60. Suzuki S, Suzuki M, Sembon S, Fuchimoto D, Onishi A (2013) Characterization of mechanisms of oxatamate on porcine preadipocytes and adipocytes differentiated in vitro. Biochim Biophys Res Commun 432:92–98.

61. Spiegelman BM, Puigserver P, Wu Z (2000) Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 24 Suppl 4:S8–S10.

62. Tang QQ, Lane MD (2012) Adipogenesis from stem cell to adipocyte. Annu Rev Biochem 81:715–736.

63. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244–251.

64. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435.

65. Medvedev AV, Snedden SK, Raimbault S, Ricquier D, Collins S (2001) Peroxisome proliferator-activated receptor-gamma-dependent activation of pyruvate dehydrogenase kinase-4 in non-alcoholic insulin resistant human adipocytes. Proc Natl Acad Sci USA 98:1147–1151.

66. Vigneri-Bascands N, Sahlburn-Blache JS, Dandine M, Dauzats M, Daviaud D, et al. (1999) Increase in uncoupling protein-2 mRNA expression by BRL49653 in vivo. Biochim Biophys Acta 1447:120–125.

67. Shimokawa T, Kato M, Watanabe Y, Hirayama R, Kurosaki E, et al. (1998) In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in Zucker diabetic fatty rats. Biochem Pharmacol 56:115–119.